Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Mar 12, 2018 8:35pm
93 Views
Post# 27703968

RE:RE:RE:Philippe Dubuc, chef de la direction financière de Theratech

RE:RE:RE:Philippe Dubuc, chef de la direction financière de Theratech
PoorOpinion wrote:
Dyno7 wrote: LES CHIFFRES:

600,000 patients traits aux anti-viraux aux USA
4%  de ceux-ci sont rsistants au traitement
20,000 25,000 patients cibles pour le Trogarzo
118,000$ US par anne pour le Trogarzo
March potentiel 5 10 fois les ventes d'Egrifta qui ont t de 43,000,000$


Does this constitute the first earning estimate from the management since approval?

Presumably he's only talking about Thera's earning and presumably he's talking about peak earnings and presumably its in CAD.
5-10 times 43mil is 215-430 mil CAD per year!!!


Listening to it again its not clear whether he's talking about thera's share of the sales or the market as a whole. The questioner asks about the potential for earning growth for the company (he asks will it grow 3 or 4 times). And Philip responds by talking about the potential market size, so not necessarily just Thera revenue.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities